SCHEMBL22797191

SCHEMBL22797191

COc1cc(-c2ccc(C)c(O)c2)cnn1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GABRG2 P18507 4/20 0.53
GABRB3 P28472 4/20 0.53
GABRA5 P31644 4/20 0.53
GABRA3 P34903 4/20 0.53
GABRA1 P14867 2/20 0.38
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
KDM1A O60341 1/20 0.36
CYP11B1 P15538 4/20 0.36
CYP11B2 P19099 4/20 0.36
CYP2A6 P11509 1/20 0.36
TSHR P16473 1/20 0.35
CASP1 P29466 1/20 0.35
RAF1 P04049 1/20 0.35
BRAF P15056 1/20 0.35
PDE10A Q9Y233 1/20 0.34
FYN P06241 1/20 0.34
ERN1 O75460 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23484599 0.83 GABRG2 (0.51) GABRG2GABRB3GABRA5GABRA3GABRA1
SCHEMBL22214048 0.80 GABRG2 (0.49) GABRG2GABRB3GABRA5GABRA3GABRA1
SCHEMBL22313714 0.80 GABRG2 (0.49) GABRG2GABRB3GABRA5GABRA3GABRA1
SCHEMBL22797385 0.79 S1PR1 (0.49) CYP2A6
SCHEMBL22313025 0.76 GABRG2 (0.45) GABRG2GABRB3GABRA5GABRA3GABRA1
SCHEMBL29431751 0.75 GABRG2 (0.67) GABRG2GABRB3GABRA5GABRA3GABRA1
SCHEMBL47861 0.74 TSHR (0.56) HSD17B1HSD17B2KDM1ATSHRCASP1
SCHEMBL25104842 0.74 CYP11B1 (0.41) GABRG2GABRB3GABRA5GABRA3CYP11B1
SCHEMBL22313758 0.73 GABRG2 (0.42) GABRG2GABRB3GABRA5GABRA3GABRA1
SCHEMBL5153274 0.72 ESR2 (0.57)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230025130-A1 METHODS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-26 US disclosed
US-11129829-B2 Methods for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2021-09-28 US disclosed
US-20200390765-A1 METHODS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2020-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11129829-B2 Methods for modulating splicing RBM17, SNRPE, SNRPB2 GABRG2 1813/4885GABRB3 1127/4885GABRA5 2293/4885
US-20230025130-A1 METHODS FOR MODULATING SPLICING RBM17, SNRPE, SNRPB2 GABRG2 1813/4885GABRB3 1127/4885GABRA5 2293/4885
US-20200390765-A1 METHODS FOR MODULATING SPLICING RBM17, SNRPE, SNRPB2 GABRG2 1813/4885GABRB3 1127/4885GABRA5 2293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.